| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8486759 | Vaccine | 2012 | 7 Pages |
Abstract
⺠NDV-3 is safe and generally well-tolerated in healthy adults. ⺠NDV-3 elicits quick and robust B- and T-cell immune responses. ⺠A single dose induces an anamnestic rather than priming immune response. ⺠T-cell response includes increases in PBMCs producing IFN-γ and/or IL-17A. ⺠A second dose further enhances the B- and T-cell immune response.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Clint S. Schmidt, C. Jo White, Ashraf S. Ibrahim, Scott G. Filler, Yue Fu, Michael R. Yeaman, John E. Edwards Jr., John P. Hennessey Jr.,